The New York Times reported on Wednesday that the Trump administration has selected five finalists among the companies developing COVID-19 vaccine candidates. Each of these drugmakers will receive federal money plus assistance in their clinical studies and manufacturing efforts.
There's a reasonable case to be made for the U.S. government to help the companies with the most promising COVID-19 vaccine candidates. But I think the reported list raised a big question: Why wasn't Novavax (NASDAQ:NVAX) in the top five?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,